Insights

Blog Post | 04.29.25

Seventh Circuit Clarifies Limits on Advertising Payments under the AKS

Blog Post | 01.30.25

FDA Clarifies Enforcement Policy Around Communications of Scientific Information on Unapproved Uses of Drugs and Medical Devices

Blog Post | 11.05.24

Stringent Requirements for Pleading Fraud Under Rule 9(b).

Blog Post | 11.01.24

General Allegations Without Representative Examples Are Insufficient to Survive a Motion to Dismiss

Blog Post | 10.09.24

The Anatomy of a Failed Qui Tam Case: Lessons from U.S v. Radiation Therapy Services

Blog Post | 10.01.24

Future Promises of Compliance with Federal Laws Cannot Form the Basis of a False Claims Act Violation

Blog Post | 09.30.24

How Much (Information) Is Too Much? Caselaw Shines a Light on Avoiding Privilege Waiver.

Blog Post | 09.03.24

The Intricacies of Qui Tam Actions and the Role of Government Dismissals

Blog Post | 07.22.24

Navigating the Attorney-Client Privilege Waiver Tightrope

Blog Post | 06.17.24

Settling False Claims Act Cases Involves More than Just Cutting a Check to DOJ

Blog Post | 03.21.24

Encouraging Signs that DOJ May Finally Be Using Its Dismissal Authority

Blog Post | 03.19.24

Significant Implications for FCA Defendants: Second Circuit Clarifies “Willfulness” in McKesson Decision

Blog Post | 02.15.24

Monumental Reduction in FCA Damages Based on Excessive Fines Clause

Blog Post | 03.22.22

Enforceability of Non-Compete Agreements; Recent Input from the DOJ

Blog Post | 11.30.21

Who Spilled The (Kidney) Beans? 11th Circuit Unseals Private Emails in Organ Transplant Dispute

Blog Post | 06.07.21

Fifth Circuit Rules Delayed Discovery of Misappropriation Not A Bar To Suit

Blog Post | 03.12.21

DOJ Indicts Hong Kong Citizen in Attempted Trade Secrets Scheme

Blog Post | 02.16.21

2020 Medicaid Managed Care Rule Summary

Blog Post | 11.23.20

HHS Finalizes Health Plan Price Transparency Rule

Blog Post | 08.25.20

Too Much or Never Enough? Another Trade Secret Misappropriation Claim Dismissed